Sandy Macrae - 24 May 2025 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role: PRESIDENT, CEO AND DIRECTOR, Director
Signature: /s/ Prathyusha Duraibabu, Attorney-in-Fact
Issuer symbol: SGMO
Transactions as of: 24 May 2025
Net transactions value: -$3,544
Form type: 4
Filing time: 28 May 2025, 16:05:05 UTC
Previous filing: 24 Apr 2025
Next filing: 24 Jul 2025
SEC: View on sec.gov

Quoteable Key Fact

"Sandy Macrae filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 28 May 2025."

Quick Takeaways

This page summarizes Sandy Macrae's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 28 May 2025, 16:05.

What Changed

Previous filing in this sequence was filed on 24 Apr 2025.
Current net transaction value: -$3,544.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Macrae Sandy	PRESIDENT, CEO AND DIRECTOR, Director	C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND	/s/ Prathyusha Duraibabu, Attorney-in-Fact	28 May 2025	0001675687

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SGMO	Common Stock	Tax liability	$3,544	-7,488	-0.32%	$0.4733	2,318,410	24 May 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2	Includes: (a) 7,259 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 44,241 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 750,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Content

Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Includes: (a) 7,259 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 44,241 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 750,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.